Pharmacotherapy of obesity weight loss maintenance and risk reduction

Abstract

Obesity, a global health crisis, necessitates multifaceted interventions. This abstract provides a concise overview of obesity pharmacotherapy, covering its context, objectives, significance, and preliminary findings. With obesity's rising prevalence, diverse approaches are crucial. Pharmacotherapy complements lifestyle changes and surgical options. This study aims to succinctly present the current landscape of obesity pharmacotherapy, emphasizing its potential and challenges. Obesity-related ailments, like diabetes and cardiovascular diseases, impose a substantial burden on healthcare systems. Pharmacotherapy aids weight management, catering to severe obesity and unresponsive cases. Various drugs targeting appetite regulation, nutrient absorption, and energy expenditure have emerged. Medications such as orlistat, phentermine/topiramate, and bupropion/naltrexone exhibit moderate effectiveness. However, side effects and sustained treatment requirements pose difficulties.

References

1. E. Colman, "Anorectic is on trial. A half-century of Federal Regulation of prescription appetite suppressant," Am. Intern. Medicine, vol. 143, pp. 380-385, 2005.
2. E. J. Hendricks, R. B. Rotman, F. L. Green way, "How Physicians obesity specialists use drugs to treat obesity," Obesity (Silver Spring), vol. 17, pp. 1730-1735, 2009.
3. NHLBI (National Heart, Blood, and Lung Institute), "Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - The evidence reports National Institute of Health," Obes. Res., vol. Suppl, pp. 25-95, 1998.
4. R. L. Atkinson, V. S. Hubbard, "Report on the NIH workshop on Pharmacologic treatment of obesity," Am. J. Clin. Nutr., vol. 60, pp. 153-156, 1994.
5. J. L. Kuk, C. Ardern, T. G. Church, A. M. Sharma, R. Padwal, et al., "Edmonton obesity staging system: Association with weight history and mortality risk," Appl. Physiol. Nutr. Metab., vol. 36, pp. 570-576, 2011.
6. S. Daniel, T. Soleymani, W. T. Garvey, "A complication-based clinical staging of obesity to guide treatment modality and intensity," Curr. Opin. Endocrinol. Diabetes Obes., vol. 20, pp. 377-388, 2013.
7. ASBP, "Overweight and obesity evaluation and management," Aurora, CO: American Society of Bariatric Physicians, 2009.
8. C. Zhang, K. M. Rexrode, R. M. Van Dam, T. Y. Li, and F. B. Hu, "Abdominal obesity and the risk of all-cause, cardiovascular and cancer mortality: Sixteen years of follow-up in US women," Circulation, vol. 117, pp. 1624-1626, 2008.
9. T. Pischon, H. Boeing, K. Hoffmann, M. Bergmann, M. B. Schulze, et al., "General and abdominal adiposity and risk of death in Europe," N. Engl. Med., vol. 359, pp. 2105-2120, 2008.
10. C. S. Fox, J. M. Massaro, U. Hoffmann, K. M. Pou, A. Maurovich-Horvat, et al., "Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study," Circulation, vol. 116, pp. 39-48, 2007.
11. H. E. Bays, J. M. Gonzalez-Campoy, G. A. Bray, A. E. Kitabchi, D. A. Bergmann, et al., "Pathogenic potential of adipose tissues and increased visceral adiposity," Expert Rev. Cardiovasc. Ther., vol. 6, pp. 343-368, 2008.
12. A. Romero-Corral, V. K. Somers, J. Sierra-Johnson, M. D. Jansen, R. J. Thomas, et al., "Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease," Eur. Heart J., vol. 28, pp. 2087-2093, 2007.
13. A. Romero-Corral, V. K. Somers, J. Sierra-Johnson, F. KorenFeld, S. Boarin, et al., "Normal weight obesity: A risk factor for cardio metabolic dysregulation and cardiovascular mortality," Eur. Heart J., vol. 31, no. 6, pp. 737-746, 2010. DOI: 10.1093/heart/chp1487
14. ASBP, "Obesity Algorithm 2013" [Online]. Available: http://asbp.org/obesity_algorithm.html. [Accessed: September 23, 2014].
15. H. M. Connolly, J. L. Crary, M. D. Mc Goon, D. Hensrud, D. S. Edwards, et al., "Valvular heart disease associated with fenfluramine-phentermine," N. Engl. J. Med., vol. 337, pp. 581-588, 1997.
16. NIH, "Clinical guideline on the identification, evaluation, and evidence report," National Institute of Health, Obes. Res., vol. 6, suppl 2, pp. 515-2095, 1998.
17. R. F. Kushner, "Road maps for the clinical practice: Case studies in disease prevention and health promotion assessment and management of adult obesity: A primer for physicians," Chicago, IL: American Medical Association, 2003.
18. V. Show, P. Berry, N. Fitterman, A. Qaseem, "Clinical efficacy assessment subcommittee of the American College of Physicians: Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians," Ann. Intern. Med., vol. 142, pp. 525-531, 2005.
19. NGC, "National Guidelines Clearinghouse 2009" [Online]. Available: http://www.guidelines.gov. [Accessed: October 14, 2009].
20. G. Glazer, "Long-term pharmacotherapy of obesity 2000: A review of efficacy and safety," Arch. Intern. Med., vol. 161, pp. 1814-1824, 2001.
21. C. K. Haddock, W. S. Poston, P. L. Dill, J. P. Foreyt, M. Ericsson, "Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials," Int. J. Obes. Relat. Metab. Disord., vol. 26, pp. 262-273, 2002.
22. Liz, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L. R. Shugarman, et al., "Meta-analysis pharmacologic treatment of obesity," Ann. Intern. Med., vol. 142, pp. 531-546, 2005.
23. R. Padwal, L. K. Lisk, D. C. Lau, "Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials," Int. J. Obes. Relat. Metab. Disord., vol. 27, pp. 1437-1446, 2003.
24. P. G. Shekelle, S. C. Morton, M. A. Maglione, M. Suttorp, J. M. Liz, et al., "Pharmacological and surgical treatment of obesity: Evidence Report/Technology Assessment No 103," pp. 1-172, 2004.
25. T. A. Wadden, R. I. Berkowitz, L. G. Womble, D. B. Serwer, S. Phelan, R. K. Cato, et al., "Randomized trials of lifestyle modifications and pharmacotherapy for obesity," N. Engl. Med., vol. 353, pp. 2111-2120, 2005.
26. E. J. Hendricks, F. L. Green way, E. C. Westermann, A. Gupta, "Blood pressure and heart rate affect weight loss and maintenance during long-term phentermine pharmacotherapy for obesity," Obesity (Silver Spring), vol. 19, pp. 2351-2360, 2011.
27. Haddock, C. K., Poston, W. S., Foreyt, J. P., DiBartolomeo, J. J., Warner, P. O. (2008). Effectiveness of Medi fast supplement combined with obesity pharmacotherapy: A clinical program evaluation. Eating and Weight Disorders, 13, 95-101.
28. Fullerton, G., Tyler, C., Johnston, C. A., Vincent, J. P., Harris, G. E., Foreyt, J. P. (2007). Quality of life in Mexican American children following a weight management program. Obesity, 15, 2553-2556.
29. Gadde, K. M., Kolotkin, R. L., Peterson, C. A., Day, W. W. (2007). Changes in weight and quality of life in obesity patients treated with 70 primates plus phentermine. Obesity, 15, A85.
30. Summan, M. (2010). Pharmacology/Toxicology NDA Review: Fenfluramine NDA 20.2088 Phentermine QDT. In FDA/CDER (Ed.), Silver Spring, MD: Food and Drug Administration.
31. Roth, J. D., Rowland, N. E. (1999). Anorectic efficacy of the fenfluramine/phentermine combination in rats: Additivity or synergy? European Journal of Pharmacology, 373, 127-134.
32. Arch, J. R. (1981). The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice. The American Journal of Clinical Nutrition, 34, 2763-2769.
33. Roth, J. D., Rowland, N. E. (1988). Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats. Psychopharmacology (Berl), 137, 99-106.
34. Hendrick, J. E. (2014). The Eating Behavior Questionnaire: Obesity Course - Diagnosis to Treatment. Philadelphia, PA: American Society of Bariatric Physicians.
35. Hendricks, L. J., Schmidt, S. L., Green, W. F., Istratiy, Y. (2014). Treatment-induced changes in EBQ scores: Overcoming obesity course. Austin, TX: American Society of Bariatric Medicine.
36. Lorber, J. (1966). Obesity in childhood: A controlled trial of anorectic drugs. Archives of Disease in Childhood, 41, 309-312.
37. Rothman, R. B. (1996). Treatment of a 4-year-old boy with ADHD with the dopamine release phentermine. Journal of Clinical Psychiatry, 57, 308-309.
38. Spear, B. A., Barlow, S. E., Ervin, C., Ludwig, D. S., Saelens, B. E., Schetzina, K. E., et al. (2007). Recommendations for the treatment of child and adolescent overweight and obesity. Pediatrics, 120, 5254-5288.
39. Munro, J. F., Mac Cuish, A. C., Wilson, E. M., Duncan, L. J. (1968). Comparison of continuous and intermittent anorectic therapy in obesity. British Medical Journal, 1, 352-354.
40. Douglas, A., Douglas, J. G., Robertson, C. E., Munro, J. P. (1983). Plasma phentermine levels, weight loss, and side effects. International Journal of Obesity, 7, 591-595.
41. INCHEM. (2009). Phentermine. International Program on Chemical Safety. Retrieved October 14, 2009, from http://www.inchem.org/document/pims/pharma.415htm.
42. Saguner, A. M., Dur, S., Perrig, M., Schiemann, U., Stuck, A. E., Bürgi, U., et al. (2010). Risk factors promoting hypertensive crises: Evidence from a longitudinal study. American Journal of Hypertension, 23, 775-780.
43. Zolkowska, J., Rothman, R. B., Baumann, M. H. (2006). Amphetamine analogs boom plasma serotonin: Implications for cardiac and pulmonary disease. journal of Pharmacology and Experimental Therapeutics, 318, 604-610.
44. Radar, W. A., Steelman, G. M., Westermann, E. C. (2008). clinical enjoy using urge for food suppressants and SSRIs. Magazine of the Oklahoma nation medical affiliation, one zero one, 180-181.
45. Cercato, C., Roizenblatt, V. A., Leança, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., et al. (2009). A randomized double-blind placebo-controlled study of the lengthy-time period efficacy and safety of diethylpropion within the remedy of obese subjects. global magazine of weight problems, 33, 857-865.
46. Horie, N. C., Cercato, C., Mancini, M. C., Halpern, A. (2010). long-term pharmacotherapy for weight problems in aged sufferers: A retrospective evaluation of medical information from a specialized weight problems outpatient hospital. tablets & aging, 27, 497-506.
47. Stewart, D. A., Bailey, J. D., Patel, H. (1970). Tennate opens as an urge for food suppressant in the remedy of overweight youngsters. implemented Therapeutics, 12, 34-36.
48. Cass, L. J. (1961). evaluation of Phendimetrazine bitartrate as an appetite suppressant. Canadian medical association journal, 84, 1114-1116.
49. Le Riche, W. T. T., Van Belle, G. (1962). Observe Phendimetrazine bitartrate as an urge for food suppressant about dosage, weight loss, and aspect effects. Canadian scientific association journal, 87, 29-31.
50. Bray GA, Hollander P, Klein's, Kushner R, Levy B, Fitchet M, et.al.A6- month randomized, placebo-managed, dose-ranging trial of Topiramate for weight reduction in obesity.Obes Res 2003;11:722-733.
51. - Astrup A, Toubro S, Topiramate: a brand new potential Pharmacological remedy for weight problems. Obes Res 2004; 12: supply 1675-1735.
52. - Astrup A, Caterson I, Zelissen P, guy-Grand B, Carruba M, Levy B, et.al. Topiramate long-time period maintenance of weight reduction caused by a low-calorie diet in the obese challenge. Obes Res 2004; 12:1658-1669.
53. - Wilding J, V anGoalL, Rissanen A, percusses F, Fitchat M, group O-S A randomized double-blind placebo-controlled examine of the long-term efficacy and safety of Topiramate within the remedy of overweight concern Int J Obes Relat Metab Disord 2004; 28: 1399-1410.
54. - McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, WUSC, et.al.Topiramate in the long term treatment of binge consuming disorder related to weight problems J clin Psychiatry 2004;65: 1463-1469. 55- Guerd Ji Kova AL,
55. Kotwal R, McElroy SL, the response of recurrent binge consuming and weight gain to Topiramate in affected person with binge eating disorder after bariatric surgical procedure. Obes Surg 2005: 15:273-277.
56. Tata AL, Kockler DR, Topiramate for binge eating disorder associated with obesity. Ann PharmacoTher2006,forty:1993-1997.
57. Gadde, ok. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., et al. (2011). Results of low-dose, controlled-launch phentermine plus topiramate mixture on weight and related comorbidities in obese and overweight adults (triumph over): A randomized, placebo-controlled, section 3 trial. The Lancet, 377, 1341-1352.
58. Allison, D. B., Gadde, ok. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., et al. (2012). Controlled-launch phentermine/topiramate in significantly obese adults: A randomized managed trial (EQUIP). obesity (Silver Spring), 20, 330-342.
59. Garvey, W. T., Ryan, D. H., look, M., Gadde, okay. M., Allison, D. B., Peterson, C. A., et al. (2012). -yr sustained weight reduction and metabolic advantages with managed-launch phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-managed, phase 3 extension examine. the Yankee Journal of scientific vitamins, 95, 297-308.
60. Neoh, S. L., Sumithran, P., Haywood, C. J., Haulica, C. A., Lee, F. T., Proietto, J. (2014). combination phentermine and topiramate for weight protection: the primary Australian revel in. The Clinical Magazine of Australia, 201, 224-226.
61. Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., et al. (2000). Evidence for viable involvement of 5-HT2B receptors in the cardiac valvulopathy related to fenfluramine and other serotonergic medicinal drugs. move, 102, 2836-2841.
62. area. (2012). Briefing document for FDA Advisory Committee assembly: NDA 22-529 Locaserin. FDA, Silver Spring, MD, pp. 1-209.
63. - Shram MJ, Schoedel KA, BartlettC, ShazerRL, Anderson CM, supplier EM, evaluation of the abuse ability of Locaserin, a serotonin 2c(5-HT2c) receptors agonist, In leisure poly-drug customers. Clin Pharmacol Ther 2011; 89: 683-692.
64. - Smith SR, Prosser WA, Donahve DJ, Morgan ME, Anderson CM, Shanahan WR, et.al. Locaserin ( APD356), a selective five -HT(2C) agonist, reduces frame weight in overweight males' and females' obesity( silver spring) 2009;17:494-503
65. - O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized Placebo-controlled trial Locaserin for weight loss in type 2 diabetes mellitus: The BLOOM - DM take a look at, obesity ( silver spring) 2012: 20: 1426-1436.
66. -Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et.al. A twelve months randomized trial of Locaserin for weight loss in overweight and obese adults: The BLOSSOM Trial Jelin Endocrinol Metab 2011;961: 3067-3077.
67. green way FL, Dunayvich E, Tollefson G, Erickson J, bupropion and naltrexone remedy for obesity with mono remedy and Placebo. J clin Endocrinol Metab 2009; 94: 4898-4906.
68. Apovian CM, AronneL, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/ bupropionSR on weight and weight problems associated hazard thing ( COR-11) weight problems ( silver spring) 2013,21: 935-943
69. - Verpeut JL, Belmo NT, Drug protection evaluation of naltrexone /bupropion for the treatment of obesity .expert Opin drug 2014;thirteen:831-841.
70. Apolinario, J. C., & McElroy, S. L. (2004). Pharmacological procedures in the treatment of binge consuming sickness. present-day Drug goals, 5, 301-307.
71. Khazaal, Y., Chatton, A., Rusca, M., Preisig, M., Zullino, D. (2007). Long-time period topiramate treatment of psychotropic drug-triggered weight advantage: A retrospective chart evaluate. trendy health facility Psychiatry, 29, 446-449.
72. Gadde, k. M., Francisco, D. M., Wegner, H. R., II, Krishnan, k. R. R. (2003). Zonisamide for weight loss in obese adults: A randomized controlled trial. JAMA, 289, 1820-1825.
73. Shin, J. H., Gadde, ok. M., Bray, G. A. (2014). Weight modifications in overweight adults 6 months after discontinuation of double-blind zonisamide or placebo treatment. Diabetes, obesity & Metabolism, sixteen, 766-768.
74. McElroy, S. L., Kotwal, R., Guerdjikova, A. I., Welge, J. A., Nelson, E. B., Lake, ok. A., et al. (2006). Zonisamide inside the treatment of binge ingesting disease with weight problems: A randomized managed trial. The Magazine of Medical Psychiatry, 67, 1897-1906.
75. McElroy, S. L., Kotwal, R., Hudson, J. I., Nelson, E. B., Keck, P. E. (2004). Zonisamide within the remedy of binge consuming sickness: An open-label potential trial. The magazine of Medical Psychiatry, 65, 50-56.
76. Gadde, okay. M., Yonish, G. M., Foust, M. S., Wegner, H. R. (2007). Mixture remedy of zonisamide and bupropion for weight reduction in obese girls: A initial, randomized, open-label have a look at. The magazine of Scientific Psychiatry, 68, 1226-1229.
77. Wallingford, N. M., Sinnayah, P., Bymaster, F. P., Gadde, okay. M., Krishnan, R. okay., McKinney, A. A., et al. (2008). Zonisamide prevents olanzapine-associated Hyperphagia, weight benefit, and elevated blood glucose in rats. Neuropsychopharmacology, 33, 2922-2933.
78. Niswander, ok., Pi-Sunyer, X., Buse, J., Jensen, okay. H., Toft, A. D., Russell-Jones, D., et al. (2013). Weight trade with liragludite and comparator treatments: An analysis of 7 sections three trials from the liragludite diabetes improvement application. Diabetes, obesity & Metabolism, 15, 42-54.
79. Anderson, J. W., Greenway, F. L., Fujioka, ok., Gadde, okay. M., McKenny, J., O'Neil, P. M., et al. (2002). Bupropion SR complements weight reduction: A 48-week double-blind, placebo-controlled trial. obesity research, 10, 633-641.
80. Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, ok., et al. (2009). The rational layout of a mixture remedy for the treatment of obesity. obesity (Silver Spring), 17, 30-39.
81. White, J. (2009). Efficacy and protection of incretin-primarily based treatments: scientific trials information. magazine of the American Pharmacists association, 49(Suppl 1), 530-540.
82. Trujillo, M., Muffler, W. (2014). Albiglutide: a new GLP-1 receptor agonist for the remedy of kind 2 diabetes. The Annals of Pharmacotherapy, 48 (11), 1494-1501.
83. Garfield, A. S., Heisler, L. Okay. (2009). Pharmacological targeting of the serotonergic machine for the remedy of weight problems. The Magazine of body structure, 587, 49-60.
84. Heisler, L. okay., Jobst, E. E., Sutton, G. M., Zhou, L., Borok, E., Thornton-Jones, Z., et al. (2006). Serotonin reciprocally regulates melanocortin neurons to modulate food consumption. Neuron, 51, 239-249.
85. Turner, E. H., Loftis, J. M., Blackwell, A. D. (2006). Serotonin a los angeles carte: Supplementation with the serotonin precursor 5-hydroxy tryptophan. Pharmacology & Therapeutics, 109, 325-338.
86. Rothman, R. B., Baumann, M. H. (2009). appetite-suppressant cardiac valve ailment and combination pharmacotherapy. the American journal of Therapeutics, 16, 354-364.
87. Whigham, L. D., Dhurandher, N. V., Rahko, P. S., Atkinson, R. L. (2007). outcomes of weight problems: body weight and Echocardiographic reputation. global magazine of Obesity (London), 31, 850-857.
88. Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., Shen, L. Z. (2010). Improved weight reduction following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. weight problems (Silver Spring), 18, 1739-1746.